Three concentrations of the penicillanic acid sulfone, sulbactam were tested in combination with cefoperazone against 632 recent clinical bacterial isolates. Cefoperazone was effective alone (<16 Mg/mL) against 95% of Enterobacteriaceae and combined with 4 Mg/mL sulbactam inhibited 99.5% of strains. This coverage of enteric bacilli was superior to timentin (99.1%), ceftazidime (98.2%), and tobramycin (90.9%). The minimum inhibitory concentrations (MICs) of cefoperazone-susceptible strains also were markedly decreased by sulbactam (overall MIC90s, 8.0 ng/mL for cefoperazone and 1.0 fig/mL for cefoperazone and 4.0 ng/ mL for sulbactam). Sulbactam also expanded the spectrum of cefoperazone against Acinetobacter species, some rare Pseudomonas species, and Bacteroides fragilis group species. Sulbactam had direct antimicrobial activity against the acinetobacters and Pseudomonas acidovorans, but the increased activity of cefoperazone-sulbactam against some other Pseudomonas species and anaerobes was attributed to /3-lactamase inhibition. The cefoperazone MICs against /9-lactamase producing Staphylococcus species also were lowered to the level of enzyme-deficient strains. Cefoperazone bactericidal activity was improved by 4.0 Mg/mL sulbactam, and no antagonism was observed. /3-lactamase hydrolysis studies confirmed a slow hydrolysis of cefoperazone only by TEM ^-lactamases and a high-grade resistance to enzyme breakdown by sulbactam. Differential /3-lactamase affinity studies for cefoperazone and sulbactam showed potential efficacy and applications to plasmid-mediated TEM and OXA enzymes and only marginal effective sulbactam inhibition of Pseudomonas and Klebsiella species enzymes. Disk diffusion studies on 556 strains confirmed the applicability of the cefoperazone 75-/ig disk to testing routine isolates other than enterococci and methicillin-resistant Staphylococcus aureus. The addition of 4.0 /ug sulbactam/mL in a fixed concentration to dilution test systems and 15 ^g sulbactam to the 75 \t% cefoperazone disk were recommended for in vitro tests. Susceptibility and resistant interpretive criteria for the disk and dilution tests can be applied with confidence. Only 0.4% false-susceptibility errors and a 97.5% absolute interpretive agreement were achieved using the 75 Mg cefoperazone/15 ng sulbactam disk.
THE WIDE-SPECTRUM "third-generation" cephalosporins have become well accepted for use against problem bacterial infections and/or as a replacement for some combination chemotherapy regimens. 7 Among these antimicrobial agents, several possess (3-lactamase stability against most clinically important enzymes and have significant activity against the Enterobacteriaceae, pseudomonads, gram-positive cocci (except enterococci), anaerobes, Neisseria species, and Haemophilus species. 1,3-4,8~ 10.13,14,21,25 However, some bacterial ^-lactamases have been demonstrated to hydrolyze these cephalosporins such as cefoperazone, cefotaxime, and, more rarely, the 7-methoxy-cephalosporins and ceftazidime. 3 ' 7 " 91314 To increase the already broad-spectrum of these drugs, several have been combined with /3-lactamase inhibitors such as clavulanic acid and sulbactam, formerly CP-45,899. 4 -61219 - 25 The penicillanic acid sulfone, sulbactam, appears to be very biologically and enzymatically stable compared with clavulanate. Retsema and associates reported the use of sulbactam-penicillin combinations to expand their antimicrobial activity, especially against plasmid-mediated ^-lactamases and those found in Bacteroides strains. ' 9 Since some of the newer cephalosporins are inactivated by the anaerobic organism /3-lactamases, sulbactam has been associated most often with cefoperazone. 4 ,52 ' , 24 ' 25 These data suggest that the cefoperazonesulbactam combination should increase the cefoperazone activity against the enteric bacilli, Haemophilus species, and Neisseria species with TEM-like /8-lactamases, some non-Enterobacteriaceae with enzymes inhibited by sulbactam and gram-negative anaerobes such as Bacteroides fragilis group strains. In an earlier study (Wilson and associates, personal communication), experiments confirmed application of this combination to a small number of the Enterobacteriaceae, Acinetobacter species, Hae-mophilus influenzae, Neisseria gonorrhoeae, and the staphylococci.
In this report we extend our investigations (1) to a wider group of pseudomonas-active comparison drugs and a inhibitor combination (ticarcillin-clavulanic acid) tested against a new recently collected bacterial population from six geographically dispersed areas of the United States and selected strains from the Centers for Disease Control; (2) to the study of more /3-lactamases, thus evaluating the cefoperazone-sulbactam combination's use on other bacterial species; (3) to study the combination's effect on bactericidal activity and inoculum effects against a wide variety of pathogens; (4) to anaerobic isolates from the B. fragilis group; and (5) to determine preliminary in vitro disk diffusion test criteria for the cefoperazone-sulbactam combination (75/5 ^g and 75/15 ng disk concentrations). 
Materials and Methods

Antimicrobial Agents
Antimicrobial Susceptibility and ^-Lactamase Testing Methods
The minimum inhibitory concentrations (MICs) were determined by the broth microdilution method described in detail in previous publications 1, 9 ,l° and by the National Committee for Clinical Laboratory Standards (NCCLS). 16 The inoculum contained 5 X 10 5 CFU/mL, and the MIC was read as the lowest antimicrobial concentration completely inhibiting bacterial growth in a well after 16-20 h of incubation at 35 °C. /3-lactamase tests were performed with nitrocefin reagent in microdilution trays.
Disk diffusion tests were performed on 556 (N. gonorrhoeae and Bacteroides species excluded) of the organisms by the method of Bauer and associates, modified/ standardized by tne NCCLS. 17 Interpretive zone standards were selected by correlating millimeter zone diameters with MIC values expressed in Mg/mL, using both the regression analysis method of least squares and error-rate bounded method of Metzler and DeHaan. 15 The 75 ng cefoperazone disks used in the regression line experiments were prepared by BBL Microbiology Systems (Cockeysville, MD). Five and 15 ng of sulbactam were added by the investigators to two lots and later correlated with MICs of cefoperazone having a supplemental fixed concentration of either 1.0, 2.0, or 4.0 Mg/mL of sulbactam. The results were compared with those suggested by Jones and colleagues, Thornsberry and associates, or published in the NCCLS M2-A3, Table 2 ."-17 ' 23 Minimal bactericidal activities and the effects of inoculum size were studied by testing 98 selected strains in the microdilution test panels. The minimum bactericidal concentrations (MBCs) were determined by subculturing 5-10 nL from each well to drug-free blood agar plates. The MBC was defined as the lowest concentration that displayed specified colony counts upon subculture (99.9% "kill"), applying methods and principles discussed by Pearson and associates. 18 The /3-lactamase hydrolysis analysis was performed on a scanning UV spectrophotometer (Perkin-Elmer, Norwalk, CN) at the appropriate wavelength (AE max ) for each /3-lactam. These cephalosporin and related substrates were diluted in 0.5 M phosphate buffer (pH 7.0) to a final concentration of 10~4 M (100 HM) in a 1.0 mL total volume at 37 °C. Reaction mixtures were monitored for a max- Citrobacter diversus (10) Chrobacier freundii (10) Enierobacter aerogenes (20) Enterobacier agglomerans (10) Enierobacler cloacae (20) Escherichia coli (25) Klebsiella pneumoniae (25) Morganella morganii (9) Proteus mirabilis (25) Proteus vulgaris (10) imum of 15-20 minutes in a continuous wvelength mode. 8, 9, 20 Inhibition studies were performed in a centrifugal-fast analyzer (CentrifiChem; Union Carbide, Tarrytdwn, NY) at a final volume of 0.5 mL, under the conditions described above. The reaction mixtures consisted of a labile /3-lactam substrate (nitrocefin or PAD AC) combined with four or five log )0 dilutions (0.1-1,000 HM) of each /3-lactam or control drug used as an inhibitor. These and other inhibition test methods have been described previously. 8 ' 9 The ten ^-lactamase enzyme preparations were made by methods described before 8 ' 9 from organisms known to produce various Richmond-Sykes types of /^-lactamase. 20 A single commercially prepared penicillinase (BBL Microbiology Systems, Cockeysville, MD) derived from Bacillus cereus was also studied. Table 1 shows the cumulative percentages of test strains inhibited by increasing concentrations of cefoperazone alone or in combination with sulbactam compared with three other potent antimicrobials (ticarcillin + clavulanic acid, ceftazidime and tobramycin). Three sulbactam concentrations (1.0, 2.0, and 4.0 Mg/mL) were tested combined with cefoperazone. The results at 4.0 Mg/mL were essentially identical to those at 2.0 Mg/mL; therefore, only the two lowest sulfdne concentrations are shown. Cefoperazone alone against these routine typical Enterobacteriaceae strains inhibited 209 of 220 (95%) isolates. When 2.0 Mg/mL sulbactam was added, nine of the resistant strains were converted to susceptible (cefoperazone MIC <, 16 /ig/mL) and of the two remaining resistant Providencia rettgeri strains, one was susceptible by adding 4.0 /xg/mL of the enzyme inhibitor. Therefore, the combination was 99.5% effective against these strains using a fixed 4.0 /ig/mL sulbactam concentration.
Results
Antimicrobial Activity of Cefoperazone-Sulbactam
Examination of the MIC90 results for all species showed 1 to 4 log 2 dilution MIC reductions for all species except P. mirabilis, an organism very susceptible to cefoperazone alone (cefoperazone MIC90 < 0.12 /ig/mL or off-scale). The range of cefoperazohe MIC90s was ^0.12 to 64 /ig/ mL and cefoperazone + 2.0 ng sulbactam/mL was ^0.12 to 32 /ig/mL. The MIC90s for all tested strains were 8.0 /ig/mL and 1.0 Mg/mL for cefoperazone and the highest combination, respectively, thus showing a remarkable reduction in these cefoperazone MICs within the susceptible range. The cefoperazone MIC90s for E. aerogenes and K. pneumoniae were decreased eight-fold and those of E. cloacae and E. coli, 16-fold.
The comparison penicillin-enzyme inhibitor combination drug, timentin, was tested using a fixed combination of 4.0 Mg/mL clavulanic acid. 6 The timentin MlC90s ranged from 1.0 to 64 /tg/mL, with only two strains of E. aerogenes considered resistant (MIC ^ 128 Mg/mL). The highest timentin MICs were routinely found among the E. aerogenes, E. cloacae, P. rettgeri, and S. marcescens isolates. Timentin was most potent against the Proteus species. Ceftazidime, a third-generation pseudomonas-active cephalosporin, was effective on 216 of 220 (98.2%) isolates. The resistant organisms were E. aerogenes (two strains), E. cloacae, and M. morganii. Like timentin, ceftazidime was most active against the Proteae (MIC90 < 0.12 jug/mL). Twenty of the enteric bacilli were resistant to tobramycin, 80% of these being Providencia species. This very active aminoglycoside was less active than any of the tested /3-lactams.
The results of susceptibility testing the nonenteric bacilli and B. fragilis group strains are found in Table 2 . The Acinetobacter species strains were inhibited by all tested comparison drugs at clinically achievable levels. Cefoperazohe-sulbactam was the most active principally because of sulbactam's antimicrobial activity on this species and its synergistic interaction with cefoperazone. Although the cefoperazone P. aeruginosa MIC90 was reduced to 8.0 rig/mh by the addition of sulbactam, no resistant strains became susceptible. Minimal increased spectrum effects were observed on the other Pseudomonas species by the combination. All the comparison drugs were excellent against P. aeruginosa, but their activity against the other Pseudomonas would be ranked (by number of species inhibited at susceptible concentrations): ceftazidime > cefoperazone-sulbactam > timentin > cefoperazone alone = tobramycin.
Sulbactam markedly reduced the B. fragilis group species cefoperazone MICs, increasing the susceptible organism population from 53.3 to 100% with 2.0 Mg/mL sulbactam added. No further reduction in cefoperazone MICs were observed with these strains when the inhibitor concentration was increased from 2.0 to 4.0 Mg/mL. Other comparison drugs were not tested.
The gram-positive cocci, H. influenzae and Neisseria species MIC statistics are shown in Table 3 . The addition of sulbactam at S; 1.0 jig/mL to cefoperazone reduced its S. aureus and 5. epidermidis MIC90s twofold to fourfold for the penicillinase-producing strains. No significant effect was observed for /3-lactamase-deficient isolates, the Streptococcus species, the H. influenzae, and the Neisseria species. The comparison drugs were generally less active and of poorer spectrum than cefoperazone or cefoperazone-sulbactam against these genera. No antagonism was observed against the species very susceptible to cefoperazone alone. Table 4 shows the MBC/MIC ratios of 98 organisms tested against cefoperazone alone or in combination with 4.0 /ug/mL sulbactam. The results with 2.0 iig/mL sulbactam were nearly identical to those of the 4.0 /ig/mL concentration and the 1.0 ng/mh inhibitor concentration produced combination MBCs most similar to cefoperazone tested alone. The presence of the sulfone produced more MBCs within one log 2 dilution of the MIC, i.e., 98.9% versus 91.8%. Dramatic reductions in MBC values were observed for E. aerogenes (one strain), ProteusProvidencia-Morganella (four strains), and S. marcescens (one strain).
Bactericidal Activity of Cefoperazone and Sulbactam
Inoculum concentration effects on the combination's MIC were tested at 10 , and 10 7 CFU/mL (data not shown). The MICs of these 98 strains were not significantly increased when the change was from 10 3 to 10 5 CFU/mL. However, when the inoculum was 10 7 CFU/mL, a marked increase was seen among a minority of strains within the Enterobacter species and the indole positive Proteae group. The addition of sulbactam moderated the increases for some E. coli and S. marcescens strains, showing some MIC elevations for cefoperazone tested alone. 
^-Lactamase Hydrolysis and Inhibition Studies
Six /3-lactamase enzymes were tested against six ^-lactam substrates (Table 5 ). These data show that the /3-lactamase inhibitors, sulbactam and clavulanic acid, were very stable to the commonly encountered, clinically relevant enzymes. 22 Similarly, the newer cephalosporins, cefotaxime and moxalactam, were not significantly hydrolyzed. The cefoperazone breakdown by TEM-1 and TEM-2 (Types Ilia and Illb) enzymes was 19-25%, compared with nitrocefin and 56-87% compared with the "firstgeneration" cephalosporin, cephaloridine. These results were consistent with our earlier studies and those reported by other investigators. The differential affinities of cefoperazone and sulbactam for a wide variety of /3-lactamases are shown in Table 6 using two chromogen substrates in most experiments. The /iM inhibitor or cefoperazone concentration causing a 50% reduction in the chromogen hydrolysis rate was recorded and ratios (cefoperazone/sulbactam) calculated for potential efficacy. Favorable protective ratios (>1.0) were found for plasmid-mediated ubiquitous TEM and OXA enzymes. 22 These ratios ranged from 8.3 to >333. The ability of sulbactam to significantly inhibit the other plasmid-mediated (PSE) and chromosomal (Types I and IV) /3-lactamases seemed poor in the presence of cefoperazone. £ l   10  10  7  10  8  9  10  10  5  5  4  7  8  8  8  10  7  8  9  8  76  85   2   -2  -1  ---1  3  4  2  1  2  2  -2  1  1  2  14  10 S;4 t pM/minute/mL partially purified ^-lactamase preparation. % RHR " relative hydrolysis rate comapred with that of nitrocefin expressed as a value of 100%. The ^-lactamase hydrolysis was determined by the UV-spectrophotometric method using 242-482 nm at 37° C. Reaction mixtures were at a total volume of 1.0 mL with 1.0 X 10"* cephalosporin substrate in 0.0S M, pH 7 phosphate bufTer.
§ NT = not typed.
However, cefoperazone has sufficient enzyme stability and antimicrobial potency against these /3-lactamases and their host species when used alone.
Disk Diffusion Susceptibility Tests with Cefoperazone-Sulbactam
All of the facultative test organisms with the exception of the N. gonorrhoeae strains were tested by the disk diffusion method 17 and their results correlated to three fixed concentrations of sulbactam added to a log2 dilution schedule of cefoperazone (0.5-256 j^g/mL). The 75-jig cefoperazone disks were tested as a procedure control and correlated to cefoperazone MICs. These regression-line data and results were compared with proposed or published NCCLS interpretive criteria. 1617 The combination disk concentrations were 75 ng of cefoperazone combined with either 5 or 15 Mg of sulbactam and the 75 ii% cefoperazone disk susceptibility criteria were applied as follows: <16 jtg/mL (^21 mm) = susceptible and ^64 Mg/mL (<15 mm) = resistant. 17 Table 7 shows the results of disk tests with 556 strains interpreted by FDA and NCCLS cefoperazone criteria.
17
As reported earlier, 1123 the most common species contributing to cefoperazone interpretive error were S.faecalis and the methicillin-resistant S. aureus (MRSA) strains. These 34 strains contributed 17 of the 46 minor errors. For the other analyses these species were omitted as sug- gested by the NCCLS standard."
17, 23 The other organism producing significant major and minor error was Acinetobacter, i.e., 2 major and 11 minor errors from only 15 tested strains. If the criteria suggested by Jones and coworkers and Thornsberry and co-workers were used, major and minor interpretive errors would have been reduced 0.7%. Only 9 of 220 tested Enterobacteriaceae showed minor interpretive errors. All other major and very major errors were contributed by single strains of Pseudomonas putida and coagulase-negative staphylococcus.
All of the sulbactam-containing cefoperazone disks performed acceptably when correlated with various cefoperazone-sulbactam dilution MIC results and utilizing the cefoperazone disk interpretive guidelines of NCCLS M2-A3.' 7 The interpretive errors contributed by the Acinetobacter strains were eliminated (13 errors) and comparable major error rates were obtained (0.4-0.8% combined) for the six MIC/zone comparisons. From these data it would appear that only very rarely isolated bacterial species would produce interpretive errors with the cefoperazone-sulbactam combinations such as Pseudomonas acidovorans, Pseudomonas cepacia, Pseudomonas fluoresces, Pseudomonas maltophilia, and P. putida. The 15-^ig sulbactam concentration would be required to routinely produce zones of S;21 mm, so the cefoperazone interpretive criteria can be applied to organisms with susceptible sulbactam MICs of ^4.0 fig/mL such as Acinetobacter species, P. acidovorans, and Neisseria species isolates.
Discussion
Cefoperazone is one of the newer broad-spectrum cephalosporins that combines nearly complete coverage of the Enterobacteriaceae with inhibition of P. aeruginosa, Neisseria species, Haemophilus species, methicillin-susceptible Staphylococcus species, streptococci other than enterococci, and most anaerobes. 1 ' 25 Several potential "flaws" have been cited in the cefoperazone spectrum that stimulated investigations resulting in the cephalosporin//3-lactamase inhibitor combination, cefoperazone and sulbactam.
7 " 9 The most important "flaws" in the cefoperazone spectrum appear to be strong TEM /3-lactamase producing enteric bacilli, Acinetobacter species and B. fragilis group anaerobes producing a potent cephalosporinase. Certainly the qualities of the penicillanic acid sulfone, sulbactam, combined with cefoperazone, have corrected most of these problems as demonstrated by some earlier investigations and this study.
3 " 5-8 " 10.13,19,24.25 j n addition, sulbactam and cefoperazone both have modest antimicrobial activity against the Legionella species. 12 Against routine bacterial isolates, cefoperazone-sulbactam should inhibit >99% of the Enterobacteriaceae and S. aureus. The direct antimicrobial activity of sulbactam will enhance the combinations spectrum against the Acinetobacter species and some non-aeruginosa pseudomonads. Other favorable changes will be the significant lowering (^fourfold) of already low or susceptible range cefoperazone MICs for nearly all enteric bacilli, the penicillinase-producing staphylococci and gonococci, the /8-lactamase-positive H. influenzae, and, more importantly, expanding the cefoperazone spectrum to nearly 100% against Bacteroides species.
In vitro tests with sulbactam containing 75 ng cefoperazone disks performed well, and we recommend at least a 4.0 Mg/mL fixed concentration of sulbactam in cefoperazone dilution schedules correlated to disks containing a minimum of 15 ^g sulbactam. The disk diffusion tests with sulbactam and ampicillin utilize a minimum of 10 ng sulbactam with good results. 2 Infrequently isolated facultative strains required >4.0 fig sulbactam/mL dilution test concentrations or > 15 ng disk content to exhibit enzyme inhibition and/or their inherent susceptibility to sulbactam (mm zones ^ 21 mm). Studies by Crosby and Gump, and Wise and co-workers suggest that higher sulbactam concentrations might be necessary to inhibit some B. fragilis group species enzymes. 4, 24 If in vivo drug concentrations with routine therapeutic doses can achieve these high sulbactam concentrations (5:4.0 /ug/mL), then specific in vitro tests such as disk-broth elution methods should be developed, specifically for anaerobe testing. Further testing of larger numbers of cefoperazone-resistant enteric bacilli also will be required to finalize the interpretive standards for the cefoperazone-sulbactam disk, only 11 resistant strains were found among the Enterobacteriaceae in this study of routine clinical isolates.
We predict a wide application of this combination drug to the inhibition of enteric bacilli covering the most clinically prevalent plasmid-mediated ^-lactamases, TEM and OXA. 22 With its added spectrum against Acinetobacter species and P. acidovorans by direct sulbactam antimicrobial effect and inhibition of Bacteroides species enzymes, cefoperazone-sulbactam possesses a wider antimicrobial spectrum than any of the potent comparison drugs in this investigation. These compounds included the ticarcillin-clavulanic acid combination, ceftazidime and tobramycin, all the widest spectrum or most potent antimicrobials in their respective drug classes.
